San Francisco – December 12, 2024
Unlearn AI has emerged as a leader in AI-powered clinical trial innovation, capping off a transformative year with major funding, product launches, and strategic collaborations. The company is redefining how clinical trials are designed and executed, particularly in the field of neurology.
$50M Series C Fuels Growth and Innovation
In 2024, Unlearn raised $50 million in Series C funding, led by Altimeter Capital with participation from Radical Ventures and Mubadala Capital, bringing its total funding to over $130 million. This capital is driving expansion in:
- Commercial and product development teams
- Enhancement of Digital Twin Generators (DTGs), Unlearn’s AI-powered engine for optimizing clinical trial design
TrialPioneer: A New Standard in Clinical Trial Optimization
Unlearn introduced TrialPioneer, a web-based AI platform that empowers pharmaceutical and biotech companies to:
- Optimize trial design using real-time data
- Forecast sample size, enrollment timelines, and statistical power
- Streamline decision-making and accelerate trial planning
Strategic Collaborations Advancing Neurological R&D
Unlearn AI formed key partnerships that are transforming research in neurodegenerative diseases:
- Alzheimer’s Disease: In partnership with AbbVie and Johnson & Johnson Innovative Medicine, Unlearn showcased how digital twins improve trial efficiency by reducing control arm size and increasing statistical confidence.
- ALS (Amyotrophic Lateral Sclerosis):
- Collaborating with ProJenX on a Phase 1 trial for prosetin (PRO-101).
- Working with APST Research to enhance ALS digital twin accuracy through expanded data and patient-specific modeling.
Leadership Evolution: Poised for Scale
Unlearn announced the appointment of Steve Herne as CEO, with founder Charles Fisher moving into a strategic board leadership role. This transition sets the stage for broader adoption of Unlearn’s AI-driven solutions across the global biopharma landscape.
“2024 has been a transformational year for Unlearn,” said Herne. “As we move into 2025, we remain committed to advancing AI-powered clinical development, accelerating trial timelines, and delivering meaningful impact for researchers, sponsors, and patients.”
About Unlearn AI
Unlearn AI is pioneering the use of AI-generated digital twins in clinical trials to improve efficiency, accuracy, and regulatory alignment. Recognized by global agencies, Unlearn’s technology is FDA-compliant and EMA-qualified for Phase 3 clinical trials, positioning the company at the forefront of AI-driven research.
By
